Infliximab therapeutic drug monitoring (TDM) in IBD can significantly reduce unnecessary use of the TNF inhibitor and has the potential to offer substantial cost savings, Austraian research shows. A study of all public TDM of infliximab for IBD across Australia between 1 July 2016 and 31 July 2017 has shown infliximab use could be reduced ...
TDM shows where unnecessary use of IFX can be stopped in IBD patients
By Mardi Chapman
8 Nov 2019